Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)P. Joly, Enno Schmidt, F. Caux et al.|Journal of the European Academy of Dermatology and Venereology|2020Cited by 332
Updated<scp>S2</scp>K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>)Luca Borradori, Gang Wang, Nina van Beek et al.|Journal of the European Academy of Dermatology and Venereology|2022Cited by 247
Severity and Phenotype of Bullous Pemphigoid Relate to Autoantibody Profile Against the NH2- and COOH-Terminal Regions of the BP180 EctodomainSilke Hofmann, Luca Borradori, Sybille Thoma-Uszynski et al.|Journal of Investigative Dermatology|2002Cited by 186
Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases<sup>§</sup>Michael Hertl, Sonja Wolff‐Franke, Detlef Zillikens et al.|JDDG Journal der Deutschen Dermatologischen Gesellschaft|2008Cited by 137
Empfehlungen für den Einsatz von Rituximab (anti‐CD20‐Antikörper) bei bullösen Autoimmundermatosen<sup>§</sup>Michael Hertl, Sonja Wolff‐Franke, Detlef Zillikens et al.|JDDG Journal der Deutschen Dermatologischen Gesellschaft|2008Cited by 1